drugset / Trial / NCT00121134
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Completed
164 enrolled
Harold J. Burstein, MD, PhD
Beth Israel Deaconess Medical Center · collabGenentech, Inc. · collabIndiana University · collabUniversity of California, San Francisco · collabUniversity of North Carolina · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to: * Examine the safety of these drugs * See how easy or difficult it is to be treated with them * Monitor for any signs of recurrent cancer * Look at blood markers that might indicate how the treatment is working
Timeline
- Start
- 2005-06
- Primary completion
- 2009-05
- Completion
- 2011-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 2000 mg/m2 | Oral |
| Subject | Cyclophosphamide | Other / unclassified | — | Oral |
| Subject | Methotrexate | Small molecule | — | Oral |